Devyser Diagnostics AB (publ)

BST:OL0 Stock Report

Market Cap: €190.0m

Devyser Diagnostics Valuation

Is OL0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OL0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OL0 (€11.15) is trading below our estimate of fair value (€35.07)

Significantly Below Fair Value: OL0 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for OL0?

Other financial metrics that can be useful for relative valuation.

OL0 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.3x
Enterprise Value/EBITDA-41.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does OL0's PS Ratio compare to its peers?

The above table shows the PS ratio for OL0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.8x
HPHA Heidelberg Pharma
11.9x12.3%€113.7m
2INV 2invest
7.8xn/a€60.4m
FYB Formycon
15.3x32.5%€930.5m
MDG1 Medigene
4.2x16.1%€31.2m
OL0 Devyser Diagnostics
11x25.4%€2.2b

Price-To-Sales vs Peers: OL0 is expensive based on its Price-To-Sales Ratio (11x) compared to the peer average (9.8x).


Price to Earnings Ratio vs Industry

How does OL0's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.6%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.6%
n/an/an/a
No more companies

Price-To-Sales vs Industry: OL0 is expensive based on its Price-To-Sales Ratio (11x) compared to the European Biotechs industry average (8.8x).


Price to Sales Ratio vs Fair Ratio

What is OL0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OL0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11x
Fair PS Ratio3.3x

Price-To-Sales vs Fair Ratio: OL0 is expensive based on its Price-To-Sales Ratio (11x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OL0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€11.15
€13.89
+24.6%
14.6%€16.87€11.74n/a4
Oct ’25€10.80
€13.88
+28.5%
14.6%€16.86€11.74n/a4
Sep ’25€9.82
€11.25
+14.6%
3.1%€11.74€10.93n/a3
Aug ’25€9.62
€11.35
+17.9%
2.3%€11.60€11.09n/a2
Jul ’25€9.52
€10.80
+13.5%
1.6%€10.97€10.63n/a2
Jun ’25€8.78
€10.83
+23.3%
1.3%€10.97€10.68n/a2
May ’25€8.10
€11.05
+36.4%
3.2%€11.41€10.69n/a2
Apr ’25€8.46
€10.29
+21.7%
10.8%€11.41€8.78n/a3
Mar ’25€7.90
€10.12
+28.1%
10.6%€11.41€8.77n/a3
Feb ’25€7.78
€9.91
+27.4%
9.1%€10.98€8.77n/a3
Jan ’25€6.82
€9.91
+45.3%
9.1%€10.98€8.77n/a3
Dec ’24€6.30
€9.91
+57.3%
9.1%€10.98€8.77n/a3
Nov ’24€5.04
€9.83
+95.1%
9.6%€11.08€8.78n/a3
Oct ’24€5.64
€9.83
+74.4%
9.6%€11.08€8.78€10.803
Sep ’24€5.98
€9.93
+66.1%
9.4%€11.07€8.77€9.823
Aug ’24€6.44
€10.71
+66.3%
13.1%€12.68€9.50€9.623
Jul ’24€6.38
€10.76
+68.7%
12.8%€12.69€9.51€9.523
Jun ’24€6.72
€10.76
+60.1%
12.8%€12.69€9.51€8.783
May ’24€7.34
€9.86
+34.4%
9.7%€11.19€8.97€8.103
Apr ’24€6.14
€9.86
+60.6%
9.7%€11.19€8.97€8.463
Mar ’24€6.76
€9.89
+46.3%
9.6%€11.19€8.97€7.903
Feb ’24€6.26
€10.82
+72.9%
3.5%€11.20€10.45€7.782
Jan ’24€6.12
€10.82
+76.9%
3.5%€11.20€10.45€6.822
Dec ’23€5.98
€10.82
+81.0%
3.5%€11.20€10.45€6.302
Nov ’23€5.44
€10.89
+100.2%
3.2%€11.24€10.54€5.042
Oct ’23€5.54
€11.91
+115.0%
5.5%€12.57€11.25€5.642

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies